Tolerability, Safety and Efficacy of Lubricin Eye Drops vs Sodium Hyaluronate Eye Drops in Subjects With Mod. Dry Eye
Primary Purpose
Dry Eye Syndrome, Tear Film Insufficiency
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Lubricin
Sodium Hyaluronate
Sponsored by
About this trial
This is an interventional treatment trial for Dry Eye Syndrome focused on measuring Dry Eye
Eligibility Criteria
Inclusion Criteria:
To be checked at the screening visit (V1) from day -14 to day -8 days before run-in period and confirmed at baseline visit (V2):
- Subjects 18 years of age or older.
- Subjects with moderate dry eye characterized by tear film osmolarity > 312 mOsm
- Subjects with both VAS for frequency and severity of symptoms, SANDE items, at screening & baseline > 25 mm (SANDE overall score > 25 mm).
- Subjects with moderate dry eye characterized by at least one eye with signs and symptoms of moderate dry eye (grade 2 or 3 of the 2007 DEWS report)
- Subjects diagnosed with dry eye from at least 6 months (current use or recommended use of artificial tears/lubricants for the treatment of Dry Eye)
- Best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units in both eyes at the time of study enrolment.
- The Informed Consent by approved Ethics Committees should be signed by the subject before any study procedures.
Exclusion Criteria:
- Evidence of an active ocular infection in either eye
- History or presence of ocular surface disorders not related to dry eye in either eye
- History or evidence of eyelid abnormality in either eye
- Use of topical cyclosporine, topical corticosteroids or any other topical medication for the treatment of dry eye in either eye within 30 days of study enrolment
- History of any ocular surgery (including laser or refractive surgical procedures) in either eye within the 90 days before study enrolment. Ocular surgery will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period
- Presence or history of any ocular or systemic disorder or condition that might significantly hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct of trail procedures (e.g. ocular trauma, progressive or degenerative corneal conditions, uveitis, systemic vasculitis, collagen vascular diseases, poorly controlled diabetes, autoimmune disease, systemic infection.)
- Known hypersensitivity to one of the components of the study or procedural medications
- Participation in another clinical study at the same time as the present study or within 90 days of baseline visit
- History of drug, medication or alcohol abuse or addiction.
Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
- are currently pregnant or,
- have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,
- intend to become pregnant during the study treatment period or,
- are breast-feeding or,
- not willing to use highly effective birth control measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD during the entire course of and 30 days after the study treatment periods.
Sites / Locations
- Azienda OspedalieroUniversitaria "Policlinico Vittorio Emanuele" Presidio Ospedaliero, Gaspare Rodolico Clinica Oculistica
- Centro Eccellenza Regionale Malattie della Superficie Oculare - Università di Messina
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Lubricin
Sodium Hyaluronate
Arm Description
Lubricin 150 µg/ml eye drops solution
Sodium hyaluronate 0.13% eye drops
Outcomes
Primary Outcome Measures
SANDE
SANDE Questionnaire - TOTAL SCORE
Secondary Outcome Measures
Ocular Total Tolerability Score
VAS
Oxford score
Corneal fluorescein surface staining
Tear Osmolarity
Tear osmolarity is an important indicator of the eye surface health. <300 mOsm/L: normal; 300 < mOsm/L< 320: mild instability of the tear film; 320 < mOsm/L< 340: moderate; <340: severe.
Schirmer-I Test
Schirmer's test I (without anaesthesia)
Tear Film Break Up Time
TFBUT
Best corrected distance visual
BCVA
Corneal fluorescein surface staining (Oxford score)
The Oxford score divides corneal staining into six groups according to severity from 0 (absent) to 5 (severe). The examiner compares the overall appearance of the patient's corneal staining with a reference figure, simulating the pattern of staining encountered in dry eye disease.
IOP
Intraocular pressure
TEAE
Adverse Events occurring after the first dose of Device
Full Information
NCT ID
NCT02510235
First Posted
July 27, 2015
Last Updated
January 28, 2019
Sponsor
Dompé Farmaceutici S.p.A
1. Study Identification
Unique Protocol Identification Number
NCT02510235
Brief Title
Tolerability, Safety and Efficacy of Lubricin Eye Drops vs Sodium Hyaluronate Eye Drops in Subjects With Mod. Dry Eye
Official Title
A Randomized, Double-masked, Controlled, Non-inferiority Study to Evaluate Tolerability, Safety and Efficacy of Lubricin Eye Drops vs Sodium Hyaluronate Eye Drops Given 4 Times a Day for 4 Weeks & 1 Week Follow-up in Subjects With Dry Eye
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
March 2015 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
June 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dompé Farmaceutici S.p.A
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.
Lubricin is a mucin-like glycoprotein originally discovered in synovial fluid, as a secreted product of cells that line the joint tissues, which is present at the surface of articular cartilage and it has been investigated on its roles at the ocular surface, in normal and pathologic conditions such as dry eye.
The objective of the study is to assess the tolerability, safety and efficacy of Lubricin eye drops solution administered over 4 weeks versus sodium hyaluronate (Na-HY) eye drops solution in subjects with moderate dry eye.
Detailed Description
Dry eye, or keratoconjunctivitis sicca, is a chronic inflammatory condition of the ocular surface that may cause severe symptoms and visual impairment. The 2007 international dry eye workshop (DEWS) defined the disease as follows: "Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface".
Lubricin is a mucin-like glycoprotein originally discovered in synovial fluid, as a secreted product of cells that line the joint tissues, which is present at the surface of articular cartilage.
In vitro studies have shown that lubricin in saline buffer acts as a lubricant between various surfaces, as well as in synovial fluid, providing evidence that lubricin is a principal lubricating protein in joints. Besides the lubricating property, lubricin has been shown to exert anti-adhesive action, strain energy dissipation, and a protective effect on underlying cells.
Lubricin has been investigated on its roles at the ocular surface, in normal and pathologic conditions such as dry eye. In fact, Lubricin is a natural human protein with most potent lubricant and anti-adhesive properties present on the ocular surface and on meibonian gland. The presence of this protein at the ocular surface was first described by the team of Sullivan D.
Based on the available preclinical lubricin studies may be an important barrier to the development of corneal and conjunctival epitheliopathies in dry eyes and its use as a novel lubricating and anti-adhesive eye drop is under investigation in this clinical investigation. This clinical investigation has been designed to demonstrate that a Lubricin 150 µg/ml eye drop formulation is non-inferior to the currently most-widely used ocular surface lubricant sodium hyaluronate 0.13% in improving signs and symptoms in patients with moderate dry eye.
Up to now, there are no known anticipated adverse events associated with the use of lubricin, anyway the occurrence of side effects cannot be excluded.
It must be considered that topical treatment with lubricin or hyaluronic acid could cause local irritation or allergic reactions. There are no known contraindications to the use of lubricin or hyaluronic acid eye drops. All examinations and assessments that will be carried out during this study are non-invasive, are commonly used in the management of subjects with dry eye and pose no risk to the subjects. There are no known contraindications to the use of lubricin or hyaluronic acid eye drops. No data are available about the embryo and fetal toxicity, therefore the experimental treatment will not be allowed to pregnant women or nursing mothers and women of childbearing potential not using appropriate birth control methods.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye Syndrome, Tear Film Insufficiency
Keywords
Dry Eye
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
56 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lubricin
Arm Type
Experimental
Arm Description
Lubricin 150 µg/ml eye drops solution
Arm Title
Sodium Hyaluronate
Arm Type
Active Comparator
Arm Description
Sodium hyaluronate 0.13% eye drops
Intervention Type
Device
Intervention Name(s)
Lubricin
Intervention Description
Lubricin 150 µg/ml eye drops
Intervention Type
Device
Intervention Name(s)
Sodium Hyaluronate
Intervention Description
Sodium hyaluronate 0.13% eye drops
Primary Outcome Measure Information:
Title
SANDE
Description
SANDE Questionnaire - TOTAL SCORE
Time Frame
day 28±4
Secondary Outcome Measure Information:
Title
Ocular Total Tolerability Score
Description
VAS
Time Frame
day 28±4
Title
Oxford score
Description
Corneal fluorescein surface staining
Time Frame
day 28±4
Title
Tear Osmolarity
Description
Tear osmolarity is an important indicator of the eye surface health. <300 mOsm/L: normal; 300 < mOsm/L< 320: mild instability of the tear film; 320 < mOsm/L< 340: moderate; <340: severe.
Time Frame
day 28±4
Title
Schirmer-I Test
Description
Schirmer's test I (without anaesthesia)
Time Frame
day 28±4
Title
Tear Film Break Up Time
Description
TFBUT
Time Frame
day 28±4
Title
Best corrected distance visual
Description
BCVA
Time Frame
day 28±4
Title
Corneal fluorescein surface staining (Oxford score)
Description
The Oxford score divides corneal staining into six groups according to severity from 0 (absent) to 5 (severe). The examiner compares the overall appearance of the patient's corneal staining with a reference figure, simulating the pattern of staining encountered in dry eye disease.
Time Frame
day 28±4
Title
IOP
Description
Intraocular pressure
Time Frame
day 28±4
Title
TEAE
Description
Adverse Events occurring after the first dose of Device
Time Frame
day 28±4
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
To be checked at the screening visit (V1) from day -14 to day -8 days before run-in period and confirmed at baseline visit (V2):
Subjects 18 years of age or older.
Subjects with moderate dry eye characterized by tear film osmolarity > 312 mOsm
Subjects with both VAS for frequency and severity of symptoms, SANDE items, at screening & baseline > 25 mm (SANDE overall score > 25 mm).
Subjects with moderate dry eye characterized by at least one eye with signs and symptoms of moderate dry eye (grade 2 or 3 of the 2007 DEWS report)
Subjects diagnosed with dry eye from at least 6 months (current use or recommended use of artificial tears/lubricants for the treatment of Dry Eye)
Best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units in both eyes at the time of study enrolment.
The Informed Consent by approved Ethics Committees should be signed by the subject before any study procedures.
Exclusion Criteria:
Evidence of an active ocular infection in either eye
History or presence of ocular surface disorders not related to dry eye in either eye
History or evidence of eyelid abnormality in either eye
Use of topical cyclosporine, topical corticosteroids or any other topical medication for the treatment of dry eye in either eye within 30 days of study enrolment
History of any ocular surgery (including laser or refractive surgical procedures) in either eye within the 90 days before study enrolment. Ocular surgery will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period
Presence or history of any ocular or systemic disorder or condition that might significantly hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct of trail procedures (e.g. ocular trauma, progressive or degenerative corneal conditions, uveitis, systemic vasculitis, collagen vascular diseases, poorly controlled diabetes, autoimmune disease, systemic infection.)
Known hypersensitivity to one of the components of the study or procedural medications
Participation in another clinical study at the same time as the present study or within 90 days of baseline visit
History of drug, medication or alcohol abuse or addiction.
Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
are currently pregnant or,
have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,
intend to become pregnant during the study treatment period or,
are breast-feeding or,
not willing to use highly effective birth control measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD during the entire course of and 30 days after the study treatment periods.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Caterina Gagliano, MD
Organizational Affiliation
Policlinico Vittorio Emanuele, Pres. Osp. G. Rodolico Clinica Oculistica
Official's Role
Principal Investigator
Facility Information:
Facility Name
Azienda OspedalieroUniversitaria "Policlinico Vittorio Emanuele" Presidio Ospedaliero, Gaspare Rodolico Clinica Oculistica
City
Catania
ZIP/Postal Code
95123
Country
Italy
Facility Name
Centro Eccellenza Regionale Malattie della Superficie Oculare - Università di Messina
City
Messina
ZIP/Postal Code
98125
Country
Italy
12. IPD Sharing Statement
Learn more about this trial
Tolerability, Safety and Efficacy of Lubricin Eye Drops vs Sodium Hyaluronate Eye Drops in Subjects With Mod. Dry Eye
We'll reach out to this number within 24 hrs